Symbols

NRXP

NRx Pharmaceuticals·NASDAQ

--(--)

NRXP fundamentals

NRXP Q4 2025 Earnings

NRx Pharmaceuticals (NRXP) released its earnings on Mar 23, 2026: revenue was 1.91M (YoY --), missed estimates; EPS was -0.08 (YoY +88.95%), missed estimates.

Revenue / YoY

1.91M

EPS / YoY

-0.08

+88.95%

Report date

Mar 23, 2026

NRXP Earnings Call Summary for Q4,2025

Operational Turnaround: FY2025 loss reduced by 12% to $16.2M; $7.8M cash on hand supports 2026 operations.
Pipeline Momentum: KETAFREE (Q3 2026 approval), NRX-100 (broader depression indication), NRX-101 (DCS-TMS combo) target $750M+ ketamine market and $1B+ neuroplasticity opportunity.
Clinical Network Growth: HOPE Therapeutics expanding to 10+ clinics by year-end, with EBITDA-positive revenue.
Strategic Differentiation: Preservative-free ketamine and DCS-TMS integration position NRx for premium pricing and faster adoption.

Earnings

EPS

Revenue

Revenue & Expenses

NRXP has released its 2025 Q4 earnings report, with revenue of 983.00K, reflecting a YoY change of NaN%, and net profit of 360.00K, showing a YoY change of 103.97%. The Sankey diagram below clearly presents NRXP's revenue sources and cost distribution.

Key Indicators

NRx Pharmaceuticals (NRXP) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

NRx Pharmaceuticals (NRXP)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

NRx Pharmaceuticals (NRXP)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

NRx Pharmaceuticals (NRXP)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown